




MOUNT SINAI LIVER CANCER PROGRAM

13[™] ANNIVERSARY

LIVER CANCER: NOVEL ADVANCEMENTS IN 2018





FRIDAY, DECEMBER 14, 2018

Icahn School of Medicine at Mount Sinai

Hatch Auditorium 1468 Madison Avenue, 2nd floor New York, NY

Program Director

JOSEP M. LLOVET, MD, PhD
Professor of Medicine

Professor of Medicine Co-Director, Mount Sinai Liver Cancer Program

Sponsored by

Mount Sinai Liver Cancer Program

1st NCI recognized Liver Cancer Program in the U.S.

https://mssm.cloud-cme.com

13™ ANNIVERSARY

LIVER CANCER: NOVEL ADVANCEMENTS IN 2018

FRIDAY, DECEMBER 14, 2018

	-		D A	B 4
PH	ľU	GI	KΔ	IVI

8:30 – 9:00am Registration

9:00 – 9:10am Welcome and Opening

Ramon Parsons, MD, PhD Director. Tisch Cancer Institute

9:10 – 9:40am Achievements of Mount Sinai Liver Cancer Program 2005-18

Josep M. Llovet, MD, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

9:40 – 10:20am Hans Popper Lecture:

Introduction: Josep M. Llovet, MD, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases **HCC Incidence in the Era of DAA Drugs for HCV Infection**

Hashem B. El-Serag, MD, PhD Baylor College of Medicine

10:20 – 10:30am Coffee Break

10:30 – 11:50am PATHOGENESIS, EPIDEMIOLOGY AND DIAGNOSIS

OF LIVER CANCER

Chairman: Augusto Villanueva, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases

10:30 – 10:50am NASH Epidemics and Liver Cancer

Amon Asgharpour, MD

Division of Liver Diseases, Department of Medicine

10:50 – 11:10am Epidemiology and Surveillance of HCC

Paolo Boffetta, MD

Hematology and Medical Oncology, Oncological Sciences,

Preventive Medicine, Tisch Cancer Institute

11:10 – 11:30am The Promise of Liquid Biopsy in the Management of Liver Cancer

Augusto Villanueva, MD, PhD

Mount Sinai Liver Cancer Program, Division of Liver Diseases

11:30 – 11:50am Classical vs Molecular Pathology in Liver Cancer

M. Isabel Fiel, MD

Mount Sinai Liver Cancer Program, Department of Pathology

11:50 – 12:30pm Lunch

12:30 – 1:50pm MANAGEMENT OF LIVER CANCER

(EARLY-INTERMEDIATE STAGE):

Chairman: Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Department of Surgery

12:30 – 12:50pm Recent Advances in the Surgical Treatment of Liver Cancer

Myron Schwartz, MD

Mount Sinai Liver Cancer Program, Department of Surgery

12:50 – 1:10pm	Role of SBRT in the Treatment of HCC Kenneth Rosenzweig, MD Chair, Department of Radiation Oncology
1:10 – 1:30pm	Chemoembolization and Radioembolization in HCC Management Edward Kim, MD Mount Sinai Liver Cancer Program, Department of Radiology, Department of Surgery
1:30 – 1:50pm	Assessment of Radiological Response in Liver Cancer Sara Lewis, MD Department of Radiology
1:50 – 2:10pm	Coffee Break
2:10 – 3:30pm	MANAGEMENT OF LIVER CANCER (ADVANCED STAGE) Chairman: Josep M. Llovet, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases
2:10 – 2:50pm	Molecular Targeted Therapies in Advanced HCC Josep M. Llovet, MD, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases
2:50 – 3:10pm	Emerging Immune Therapies in Liver Cancer Max Sung, MD Mount Sinai Liver Cancer Program
3:10 – 3:30pm	Molecular Tumor Board in ISMMS Jane Houldsworth, PhD
	Division of Molecular Pathology
3:30 – 3:50pm	Coffee Break
3:30 – 3:50pm 3:50 – 5:10pm	
•	NOVEL TARGETS AND BIOMARKERS FOR LIVER CANCER TREATMENT Chairman: Samuel Waxman, MD, Mount Sinai Liver Cancer Program Department of Hematology and Medical
3:50 – 5:10pm	NOVEL TARGETS AND BIOMARKERS FOR LIVER CANCER TREATMENT Chairman: Samuel Waxman, MD, Mount Sinai Liver Cancer Program Department of Hematology and Medical Oncology, Department of Oncological Sciences Biomarkers of Response to Immune Checkpoint Inhibitors in HCC Daniela Sia, PhD
3:50 – 5:10pm 3:50 – 4:10pm	NOVEL TARGETS AND BIOMARKERS FOR LIVER CANCER TREATMENT Chairman: Samuel Waxman, MD, Mount Sinai Liver Cancer Program Department of Hematology and Medical Oncology, Department of Oncological Sciences Biomarkers of Response to Immune Checkpoint Inhibitors in HCC Daniela Sia, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases Experimental Models for Driver Identification in Liver Cancer Amaia Lujambio, PhD Mount Sinai Liver Cancer Program, Department of Oncological
3:50 – 5:10pm 3:50 – 4:10pm 4:10 – 4:30pm	NOVEL TARGETS AND BIOMARKERS FOR LIVER CANCER TREATMENT Chairman: Samuel Waxman, MD, Mount Sinai Liver Cancer Program Department of Hematology and Medical Oncology, Department of Oncological Sciences Biomarkers of Response to Immune Checkpoint Inhibitors in HCC Daniela Sia, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases Experimental Models for Driver Identification in Liver Cancer Amaia Lujambio, PhD Mount Sinai Liver Cancer Program, Department of Oncological Sciences Anti-fibrotic Agents as a Chemopreventive Approach in Liver Cancer Youngmin Lee, MD, PhD

5:10pm

Closing Remarks

MOUNT SINAI LIVER CANCER PROGRAM

13TH ANNIVERSARY

LIVER CANCER: NOVEL ADVANCEMENTS IN 2018

FRIDAY, DECEMBER 14, 2018

Icahn School of Medicine at Mount Sinai Hatch Auditorium 1468 Madison Avenue, 2nd floor New York, NY







Complimentary Online Registration https://mssm.cloud-cme.com

International Attendees \$100

Cancellation Policy: All refund and cancellation requests must be emailed to the CME office at cme@mssm.edu by December 7, 2018. Cancellations after this date are not eligible for a refund. An administrative fee of \$50 will be deducted from your refund. No refunds will be issued for registration fees that are equal to or less than \$50.







Conference Information

https://mssm.cloud-cme.com Office of CME at 212-731-7950 e-mail: cme@mssm.edu

Location

Icahn School of Medicine at Mount Sinai

Hatch Auditorium, Guggenheim Pavillion, 2nd floor. 1468 Madison Ave, New York, NY Directions and Parking: www.icahn.mssm.edu/about/visiting

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Program Director

JOSEP M. LLOVET, MD, PhD, Professor of Medicine

Co-Director, Mount Sinai Liver Cancer Program

Program Chairs

MYRON SCHWARTZ, MD, Professor of Surgery, Director of Liver Surgery

SAMUEL WAXMAN, MD, Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences

AUGUSTO VILLANUEVA, MD, PhD, Mount Sinai Liver Cancer Program, Division of Liver Diseases

Target Audience

Hepatologists and Gastroenterologist, Oncologists, Surgeons, Radiologist, Pathologists and Basic Scientists interested in liver cancer from the New York Area and beyond.

Activity Description

This conference will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) from the Mount Sinai Liver Cancer Program and one outstanding invited lecturer. The meeting is intended to provide a summary of the state-of the-art knowledge of the novel advancements reported in 2018 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

Activity Learning Objectives

- Recognize the new trends in the epidemiology of liver cancer and the impact of new anti-viral therapies.
- Review the current surgical and loco-regional treatments for liver cancer.
- Evaluate new molecular targeted therapies approved and in clinical development for HCC and cholangiocarcinoma.
- Describe novel targets and biomarkers for a precision medicine approach of liver cancer.

Registration Fee

International Attendees \$100

All Others Complimentary

Register Online at: https://mssm.cloud-cme.com

Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 7.0 *AMA PRA Category 1 Credit*(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Verification of Attendance

Verification of attendance will be provided to all professionals.

Special Needs

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

Acknowledgment

This activity is made possible in part by educational grants from:

Bayer HealthCare, Celsion Corporation, Bristol-Myers Squibb, BTG International, Eisai, Glycotest

Icahn School of Medicine at Mount Sinai

The Page and William Black Post Graduate School One Gustave L. Levy Place, Box 1193 New York, NY 10029-6574

NOVEL ADVANCEMENTS MOUNT SINAI LIVER 13TH ANNIVERSARY LIVER CANCER: IN 2018



DECEMBER 14, 2018

Hatch Auditorium, 1468 Madison Avenue, 2nd floor Icahn School of Medicine at Mount Sinai

Complimentary Online Registration https://mssm.cloud-cme.com